Biotech Values

[DewDiligence]

If there is a winner in all this, it is the pharmaceutical industry. [Drug] companies avoided several measures pushed by some Democrats that would have cut revenue, notably proposals allowing the government to negotiate the price of medicines sold through the Medicare Part D drug benefit for the elderly.

For drug/biotech investors, this is by far the most consequential non-provision in the bill.